Abstract | AIMS: METHODS AND RESULTS: Harmony Outcomes was an event-driven, multicenter, double-blind, placebo-controlled trial involving 9 463 patients > 40years of age with type-2 diabetes and established atherosclerotic cardiovascular disease. It tested the effects of albiglutide on the occurrence of a composite primary endpoint, consisting of cardiovascular death, myocardial infarction or stroke. Within this post-hoc analysis, the effects of albiglutide on myocardial infarction subtypes and other ischemic endpoints were analyzed.During the median-follow up of 1.6 years, a total of 421 patients (4.5%) experienced at least one myocardial infarction, with 72 patients having more than one event. Treatment with albiglutide reduced both first events (hazard ratio (HR)0.75 (0.62-0.91)) and overall events (HR0.75 (0.61-0.91)) as well as first type 1 (HR0.73 (0.57-0.92)) and type 2 myocardial infarctions (HR0.65 (0.46-0.92)). The effect of albiglutide treatment was consistent for ST-segment elevation (HR0.69 (0.38-1.26)) and non-ST elevation (HR0.86 (0.66-1.2) myocardial infarction. CONCLUSIONS:
|
Authors | Konstantin A Krychtiuk, Guillaume Marquis-Gravel, Shannon Murphy, Karen P Alexander, Karen Chiswell, Jennifer B Green, Lawrence A Leiter, Renato Lopes, Stefano Del Prato, William Schuyler Jones, John J V McMurray, Adrian F Hernandez, Christopher B Granger |
Journal | European heart journal. Cardiovascular pharmacotherapy
(Eur Heart J Cardiovasc Pharmacother)
(Jan 25 2024)
ISSN: 2055-6845 [Electronic] England |
PMID | 38271596
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. |